VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.616 USD | -0.19% |
|
-10.07% | -14.09% |
| Mar. 26 | Transcript : VolitionRx Limited, Q4 2023 Earnings Call, Mar 26, 2024 | |
| Mar. 26 | VolitionRx Limited announced that it has received $0.1 million in funding | CI |
Financials (USD)
| Sales 2024 * | 3.63M | Sales 2025 * | 16.48M | Capitalization | 50.65M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -32M | EV / Sales 2024 * | 11.5 x |
| Net cash position 2024 * | 8.9M | Net Debt 2025 * | 18.4M | EV / Sales 2025 * | 4.19 x |
| P/E ratio 2024 * |
-1.52
x | P/E ratio 2025 * |
-1.91
x | Employees | 110 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on VolitionRx Limited
More recommendations
More press releases
| 1 day | +0.66% | ||
| 1 week | -9.30% | ||
| Current month | -17.93% | ||
| 1 month | -26.91% | ||
| 3 months | -37.42% | ||
| 6 months | -7.27% | ||
| Current year | -13.35% |
1 week
0.57
0.71
1 month
0.570.87
Current year
0.571.23
1 year
0.552.10
3 years
0.554.14
5 years
0.556.84
10 years
0.559.28
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Terig Hughes
DFI | Director of Finance/CFO | 54 | 21-01-31 |
Gaetan Michel
COO | Chief Operating Officer | 51 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Martin Faulkes
CHM | Chairman | 80 | 11-10-05 |
Guy Innes
BRD | Director/Board Member | 67 | 11-10-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.616 | -0.19% | 245 613 |
| 24-04-18 | 0.6172 | +3.89% | 255,788 |
| 24-04-17 | 0.5941 | -4.18% | 172,749 |
| 24-04-16 | 0.62 | -8.66% | 138,711 |
| 24-04-15 | 0.6788 | -0.91% | 130,511 |
Delayed Quote Nyse, April 19, 2024 at 01:59 pm EDT
More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.6172
USD
Average target price
3.725
USD
Spread / Average Target
+503.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.35% | 50.65M | |
| -18.13% | 11.52B | |
| +37.88% | 3.27B | |
| -20.67% | 2.02B | |
| -30.68% | 1.44B | |
| +12.52% | 1.01B | |
| -6.33% | 719M | |
| -32.33% | 418M | |
| -51.63% | 339M | |
| -2.58% | 284M |
- Stock Market
- Equities
- VNRX Stock
